: Ovarian cancer poses a formidable health challenge for women globally, necessitating innovative therapeutic approaches. This review provides a succinct summary of the current research status on lipid-based nanocarriers in the context of ovarian cancer treatment. Lipid-based nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), offer a promising solution for delivering anticancer drugs with enhanced therapeutic effectiveness and reduced adverse effects. Their versatility in transporting both hydrophobic and hydrophilic medications makes them well-suited for a diverse range of anticancer drugs. Active targeting techniques like ligand-conjugation and surface modifications have been used to reduce off-target effects and achieve tumour-specific medication delivery. The study explores formulation techniques and adjustments meant to enhance drug stability and encapsulation in these nanocarriers. Encouraging results from clinical trials and preclinical investigations underscore the promise of lipid-based nanocarriers in ovarian cancer treatment, providing optimism for improved patient outcomes. Notwithstanding these advancements, challenges related to clearance, long-term stability, and scalable manufacturing persist. Successfully translating lipidbased nanocarriers into clinical practice requires addressing these hurdles. To sum up, lipidbased nanocarriers are a viable strategy to improve the effectiveness of therapy for ovarian cancer. With their more focused medication administration and lower systemic toxicity, they may completely change the way ovarian cancer is treated and increase patient survival rates. Lipidbased nanocarriers need to be further researched and developed to become a therapeutically viable treatment for ovarian cancer.

中文翻译：

---

使用脂质纳米载体改善卵巢癌治疗：最新进展概述

：卵巢癌给全球女性带来了巨大的健康挑战，需要创新的治疗方法。这篇综述简要总结了基于脂质的纳米载体在卵巢癌治疗中的当前研究状况。基于脂质的纳米载体，包括脂质体、固体脂质纳米粒子（SLN）和纳米结构脂质载体（NLC），为递送抗癌药物提供了一种有前途的解决方案，可增强治疗效果并减少不良反应。它们在运输疏水性和亲水性药物方面的多功能性使它们非常适合各种抗癌药物。配体缀合和表面修饰等主动靶向技术已被用来减少脱靶效应并实现肿瘤特异性药物输送。该研究探索了旨在增强这些纳米载体中药物稳定性和封装性的配方技术和调整。临床试验和临床前研究的令人鼓舞的结果强调了基于脂质的纳米载体在卵巢癌治疗中的前景，为改善患者的治疗结果带来了乐观情绪。尽管取得了这些进步，但与间隙、长期稳定性和可扩展制造相关的挑战仍然存在。成功地将脂质纳米载体转化为临床实践需要解决这些障碍。综上所述，脂质纳米载体是提高卵巢癌治疗效果的可行策略。凭借更集中的药物管理和更低的全身毒性，它们可能会彻底改变卵巢癌的治疗方式并提高患者的生存率。需要进一步研究和开发基于脂质的纳米载体，以成为治疗卵巢癌的可行疗法。